Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Samalin Investment Counsel LLC

Samalin Investment Counsel LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,607 shares of the biopharmaceutical company’s stock after purchasing an additional 860 shares during the period. Samalin Investment Counsel LLC’s holdings in Halozyme Therapeutics were worth $507,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $69,000. RPg Family Wealth Advisory LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $1,886,000. Retirement Systems of Alabama boosted its position in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after buying an additional 74,173 shares during the period. Shaker Investments LLC OH grew its stake in shares of Halozyme Therapeutics by 12.3% in the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock worth $3,601,000 after acquiring an additional 8,249 shares in the last quarter. Finally, Foster & Motley Inc. increased its position in shares of Halozyme Therapeutics by 118.6% during the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after acquiring an additional 12,630 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Benchmark reissued a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,697 shares of company stock valued at $1,754,451. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $65.16 on Monday. The company has a fifty day moving average of $58.20 and a two-hundred day moving average of $54.66. The company has a market capitalization of $8.05 billion, a PE ratio of 19.00, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.96. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.